Phase 1b/2 study of rebastinib (DCC-2036) in combination with paclitaxel: Preliminary safety, efficacy, pharmacokinetics and pharmacodynamics in patients with advanced or metastatic solid tumors

被引：2

作者：

Janku, Filip ^{[1
]}

Birrer, Michael ^{[2
]}

Richardson, Debra ^{[3
]}

Chu, Christina ^{[4
]}

Goel, Sanjay ^{[5
]}

Su, Ying ^{[6
]}

Matin, Bahar ^{[6
]}

Kuida, Keisuke ^{[6
]}

Ruiz-Soto, Rodrigo ^{[6
]}

Hamilton, Erika Paige ^{[7
,8
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Alabama Birmingham, Birmingham Comprehens Canc Ctr, Birmingham, AL USA

[3] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Sarah Cannon Res Inst, Oklahoma City, OK USA

[4] Fox Chase Canc Ctr, Havertown, PA USA

[5] Albert Einstein Coll Med, Bronx, NY 10467 USA

[6] Deciphera Pharmaceut LLC, Waltham, MA USA

[7] Sarah Cannon Res Inst, Nashville, TN USA

[8] Tennessee Oncol PLLC, Nashville, TN USA

来源：

关键词：

D O I：

10.1158/1535-7163.TARG-19-B055

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

B055

引用

页数：3